论文部分内容阅读
目的 比较18F 脱氧葡萄糖 (FDG)、99Tcm 甲氧基异丁基异腈 (MIBI)和111In 奥曲肽在肺癌诊断和治疗评价时的优缺点。方法 研究对象包括99Tcm MIBISPECT显像 90例 ,111In 奥曲肽SPECT显像 2 1例以及18F FDGPET显像 118例。其中 15例进行了MIBI和奥曲肽 ,7例做了FDG与MIBI 2种显像。 2 6例用MIBI,12例用FDG进行了治疗前后的比较。结果 MIBI显像对大于 1cm的肺内占位病变的诊断、鉴别诊断和治疗后评价有较好效果 ,其核素血管显像可以帮助了解肺内大血管受累情况 ,但受血流灌注和多药耐药的影响。病灶对奥曲肽的摄取显著高于MIBI(P <0 0 1) ,但两者相关性不高 (r=0 47)。PET可以发现更小的病灶 ,具有更好的图像质量。结论 MIBI显像具有较好的效价比 ,而奥曲肽显像可以更好地显示所有“存活”的肿瘤细胞。
Objectives To compare the advantages and disadvantages of 18F deoxyglucose (FDG), 99Tcm methoxyisobutylisonitrile (MIBI) and 111In octreotide in the diagnosis and treatment of lung cancer. Methods Subjects included 99 Tcm MIBI SPECT imaging in 90 cases, 111 In octreotide SPECT imaging in 21 cases, and 18 F FDG PET imaging in 118 cases. Of these, 15 were performed with MIBI and octreotide, and 7 were performed with FDG and MIBI imaging. Twenty-six patients were treated with MIBI and 12 patients were compared before and after treatment with FDG. Results MIBI imaging had better results in the diagnosis, differential diagnosis and post-treatment evaluation of pulmonary lesions larger than 1 cm. The angiographic angiography could help to understand the involvement of large vessels in the lung, but it was affected by blood flow and many Drug resistance effects. Occurrence of octreotide in lesions was significantly higher than that in MIBI (P < 0 01), but the correlation between the two was not high (r = 0 47). PET can find smaller lesions with better image quality. Conclusion MIBI imaging has a good titer ratio, while octreotide imaging can better show all “surviving” tumor cells.